Replies to post #33797 on Marker Therapeutics Inc (MRKR)

[jobynimble]

Thrilled to share that we dosed the first patient in our Phase 1 #clinicaltrial investigating MT‑601 for the treatment of patients with #lymphoma who have failed or are ineligible to receive CD19 CAR T cell treatment.
Follow the link for more details: https://t.co/roxDvLTr0n pic.twitter.com/e49gnShAgw

— Marker Therapeutics, Inc. (@MRKRTherapeutic) June 12, 2023